Do Proton Pump Inhibitors Alter the Response to Immune Checkpoint Inhibitors in Cancer Patients? A Meta-analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Feb 13

PMID 36776847

Authors

Sebastien Lopes

Lucile Pabst

Anne Dory

Marion Klotz

Benedicte Gourieux

Bruno Michel

Celine Mascaux

Affiliations

Soon will be listed here.

Abstract

Introduction: Gut microbiota can significantly affect the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival rate of patients treated by ICIs. Proton pump inhibitors (PPIs) can indeed modulate microbiota's diversity, therefore altering ICIs response. A meta-analysis was performed based on published data to verify this hypothesis.

Methods: In this study, over 41 publications, exploring the impact of concomitant PPI treatment on outcomes of ICI-treated patients, were analyzed. Evaluated endpoints were overall survival (OS) and progression-free survival (PFS). Pooled hazard ratios (HRs) with a 95% confidence interval (CI) were reported in ICIs in PPI users versus non-PPI users. Subgroup analyses were performed to minimize the impact of study heterogeneity and to investigate the influence of PPI on the different groups of interest. There was no evidence of publication bias for OS and PFS analysis in subgroup analysis.

Results: Forty-one studies were included in the meta-analysis, including a total of 20,042 patients. OS of patients receiving ICIs was negatively correlated in patients concomitantly treated with PPI (HR=1.37; 95%CI, 1.23-1.52). PFS of cancer patients receiving ICIs was also negatively correlated with PPI treatment (HR=1.28; 95%CI, 1.15-1.42). PPI and ICI use was associated with worst OS and PFS not only for non-small-cell lung cancer (NSCLC) or urothelial cancer patients but also for patients treated with anti PD-1 (OS) and anti PD-L1 (OS and PFS) immunotherapies when administered in non-first line and when PPI was received as baseline treatment or in 60 days before ICI initiation. PPI and ICI use also showed the worst OS and PFS for patients from Europe and Asia.

Conclusion: This meta-analysis suggests that PPI treatment leads to significantly worse outcomes in advanced cancer patients treated by ICIs in terms of PFS and OS.

Citing Articles

Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials.

Gamrath L, Pedersen T, Moller M, Volmer L, Holst-Christensen L, Vestermark L Curr Oncol Rep. 2025; 27(1):45-58.

PMID: 39753816 PMC: 11762419. DOI: 10.1007/s11912-024-01622-6.

Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process.

Brade A, Bahig H, Bezjak A, Juergens R, Lynden C, Marcoux N Curr Oncol. 2024; 31(11):6512-6535.

PMID: 39590114 PMC: 11593044. DOI: 10.3390/curroncol31110483.

The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma.

Wang N, Xu Y, Yang G, Chen H, Wang X, Fu J J Hepatocell Carcinoma. 2024; 11:1311-1321.

PMID: 38979082 PMC: 11230117. DOI: 10.2147/JHC.S464033.

Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC).

Del Giudice T, Staropoli N, Tassone P, Tagliaferri P, Barbieri V Cancers (Basel). 2024; 16(10).

PMID: 38791885 PMC: 11120070. DOI: 10.3390/cancers16101806.

Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence.

Sawaid I, Samson A J Clin Med. 2024; 13(7).

PMID: 38610738 PMC: 11012754. DOI: 10.3390/jcm13071970.

References

Tomisaki I, Harada M, Minato A, Nagata Y, Kimuro R, Higashijima K . Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma. Anticancer Res. 2022; 42(3):1629-1634. DOI: 10.21873/anticanres.15638. View

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F . A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019; 7(1):57. PMC: 6391761. DOI: 10.1186/s40425-019-0527-y. View

Conde-Estevez D, Monge-Escartin I, Rios-Hoyo A, Monzonis X, Echeverria-Esnal D, Moliner L . Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. J Chemother. 2020; 33(1):32-39. DOI: 10.1080/1120009X.2020.1849488. View

Li C, Xia Z, Li A, Meng J . The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ann Transl Med. 2021; 8(24):1655. PMC: 7812177. DOI: 10.21037/atm-20-7498. View

Jackson M, Goodrich J, Maxan M, Freedberg D, Abrams J, Poole A . Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016; 65(5):749-56. PMC: 4853574. DOI: 10.1136/gutjnl-2015-310861. View

Baek Y, Joo Kang E, Hong S, Park S, Kim J, Shin J . Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors. Int J Cancer. 2021; 150(8):1291-1300. DOI: 10.1002/ijc.33892. View

Sen S, Carmagnani Pestana R, Hess K, Viola G, Subbiah V . Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Ann Oncol. 2018; 29(12):2396-2398. PMC: 6311953. DOI: 10.1093/annonc/mdy453. View

Hopkins A, Kichenadasse G, Karapetis C, Rowland A, Sorich M . Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Clin Cancer Res. 2020; 26(20):5487-5493. DOI: 10.1158/1078-0432.CCR-20-1876. View

Frankel A, Coughlin L, Kim J, Froehlich T, Xie Y, Frenkel E . Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients. Neoplasia. 2017; 19(10):848-855. PMC: 5602478. DOI: 10.1016/j.neo.2017.08.004. View

10.

Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K . therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. Oncoimmunology. 2022; 11(1):2081010. PMC: 9154751. DOI: 10.1080/2162402X.2022.2081010. View

11.

Li M, Zeng C, Yao J, Ge Y, An G . The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. Int Immunopharmacol. 2020; 88:106972. DOI: 10.1016/j.intimp.2020.106972. View

12.

Gurav A, Sivaprakasam S, Bhutia Y, Boettger T, Singh N, Ganapathy V . Slc5a8, a Na+-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon that protects against colitis and colon cancer under low-fibre dietary conditions. Biochem J. 2015; 469(2):267-78. PMC: 4943859. DOI: 10.1042/BJ20150242. View

13.

Stein C, Burtey S, Mancini J, Pelletier M, Sallee M, Brunet P . Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant. 2020; 36(9):1664-1674. DOI: 10.1093/ndt/gfaa137. View

14.

Haastrup P, Thompson W, Sondergaard J, Jarbol D . Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol. 2018; 123(2):114-121. DOI: 10.1111/bcpt.13023. View

15.

Derosa L, Routy B, Thomas A, Iebba V, Zalcman G, Friard S . Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022; 28(2):315-324. PMC: 9330544. DOI: 10.1038/s41591-021-01655-5. View

16.

Rooks M, Garrett W . Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 16(6):341-52. PMC: 5541232. DOI: 10.1038/nri.2016.42. View

17.

Lee J, Hyung S, Lee J, Choi S . Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study. J Immunother Cancer. 2022; 10(8). PMC: 9413167. DOI: 10.1136/jitc-2022-005226. View

18.

Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje A . Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020; 11(1):362. PMC: 6969170. DOI: 10.1038/s41467-019-14177-z. View

19.

Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis D, Aerts J . Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021; 9(4). PMC: 8031700. DOI: 10.1136/jitc-2021-002421. View

20.

Iglesias-Santamaria A . Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer. Clin Transl Oncol. 2020; 22(9):1481-1490. DOI: 10.1007/s12094-019-02282-w. View